We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
MOTS-c (Mitochondrial ORF of the 12S rRNA Type-C)
A 16-amino-acid mitochondrial-derived peptide promoted as a metabolic regulator and 'exercise mimetic'. Honest appraisal: the evidence is almost entirely preclinical (mouse and cell studies of AMPK activation, insulin sensitivity, exercise capacity, and bone) plus human ASSOCIATION/observational studies (circulating MOTS-c vs age, metabolic status, exercise). There are essentially NO interventional human trials of administered MOTS-c — nobody has run a randomized trial giving it to people. It is not a regulated dietary supplement; injectable product is sold 'for research use only'.
Research peptide — not a dietary supplement
MOTS-c is a research compound, not a regulated dietary supplement. It is typically administered by injection and sold “for research use only.” The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most MOTS-c studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2015–2026 with a typical study size of 602 participants.
Based on 19 studies · 1 meta-analysis · 1 RCT · 723 total participants
Confidence
Moderate confidenceBy outcome
MOTS-c has coherent mouse and cell mechanisms plus human association data, but there are zero interventional trials of administered MOTS-c in people, so it scores at the bottom of Emerging.
4 trials ongoing or recruiting · none completed on ClinicalTrials.gov
Registered trials show research momentum for MOTS-c, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene — one of a small family of 'mitochondrial-derived peptides'.
It was discovered in 2015 and is framed by its discoverers as a mitochondrial signal that, under metabolic stress, translocates to the nucleus (in an AMPK-dependent way) and regulates nuclear gene expression, including antioxidant-response-element (NRF2) targets.
Mechanistically, in cells and mice it inhibits the folate–AICAR–de novo purine biosynthesis pathway, activates AMPK, and is reported to improve insulin sensitivity, increase fat oxidation, raise stress resistance, and boost physical/exercise capacity — earning the 'exercise mimetic' label.
The honest evidence picture: almost the entire functional literature is preclinical (mouse models of obesity, insulin resistance, gestational diabetes, autoimmune diabetes, osteoporosis, vascular calcification, heart failure, lung injury) plus in-vitro mechanistic work.
The human data are ASSOCIATION/observational only — circulating MOTS-c declines with age; muscle MOTS-c tracks myofiber type in healthy aging men; plasma MOTS-c responds to lipids/insulin and exercise; low circulating MOTS-c predicts adverse cardiovascular outcomes in type 2 diabetics; and a MOTS-c mtDNA polymorphism has been hypothesized to contribute to exceptional Japanese longevity.
Critically, there are NO published interventional randomized controlled trials of administered MOTS-c in humans — the metabolic and exercise 'benefits' come from rodents, and the human evidence cannot establish that injecting MOTS-c does anything in people.
MOTS-c is not an approved drug or regulated dietary supplement; injectable material is sold 'for research use only', with the attendant identity/purity/sterility risks, and long-term human effects are entirely unknown. Overall evidence is Emerging and renders as unscored: mechanistic + observational only.
In cells and mice MOTS-c activates AMP-activated protein kinase (AMPK), the cellular energy sensor, and some reported effects, such as on bone-resorbing cells, are partly blocked by AMPK inhibition. This is a preclinical mechanism; it has not been demonstrated in humans given the peptide.
MOTS-c is reported to inhibit the folate cycle and its tethered de novo purine (AICAR) biosynthesis, which drives the AMPK activation described above. Established in cell/mouse work; an indirect proposed mechanism, not validated human pharmacology.
Under metabolic stress MOTS-c translocates to the nucleus (AMPK-dependent) and regulates nuclear genes, including antioxidant-response-element targets, interacting with the stress transcription factor NRF2 (NFE2L2). Demonstrated in cells and rodents; mechanistic only.
Endogenous MOTS-c rises in muscle and circulation with exercise, and exogenous MOTS-c is reported to enhance physical capacity and metabolic adaptation in mice, leading to the 'exercise mimetic' framing. Human data show only that exercise raises MOTS-c — not that administering MOTS-c improves human performance.
How MOTS-c works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Avoid — never studied in pregnancy or lactation.
Avoid or use only under medical supervision — animal data show effects on insulin sensitivity and glucose metabolism.
Avoid — MOTS-c is an unapproved, non-permitted experimental substance marketed as an 'exercise mimetic'; its status in sport is problematic.
MOTS-c improves insulin sensitivity and glucose handling in animal models. The direction and magnitude of any interaction in humans is unknown, so combining it with glucose-lowering therapy is unpredictable and warrants caution.
Tip: There is no safe verified product; risk stems from unregulated 'research use only' sourcing rather than the peptide itself.
Tip: No human safety data exist for a peptide with broad gene-regulatory activity; absence of reported harm is not evidence of safety.
The current evidence for MOTS-c is insufficient to assign an evidence score, based on 19 indexed studies, including 1 meta-analysis. A 16-amino-acid mitochondrial-derived peptide promoted as a metabolic regulator and 'exercise mimetic'. Honest appraisal: the evidence is almost entirely preclinical (mouse and cell studies of AMPK activation, insulin sensitivity, exercise capacity, and bone) plus human ASSOCIATION/observational studies (circulating MOTS-c vs age, metabolic status, exercise). There are essentially NO interventional human trials of administered MOTS-c — nobody has run a randomized trial giving it to people. It is not a regulated dietary supplement; injectable product is sold 'for research use only'. Representative study: PMID 39160573.
Dosing for MOTS-c: No validated human dose exists. MOTS-c has never been dose-established in a published human interventional trial. Animal studies typically use ~0.5–15 mg/kg by injection in mice/rats, which does not translate to a human regimen. Anecdotal non-clinical injectable protocols circulated online have no clinical basis, no safety validation, and must not be read as a recommendation. (no cited human trial states a dose).
Timing is flexible for MOTS-c — consistent daily use matters more than the time of day. There is no evidence-based dosing schedule because no human pharmacokinetic or efficacy trial has established one.
No consumer dose of MOTS-c is endorsed, so there is no dose at which it can be called safe. Talk to a healthcare provider before taking it. Reported side effects include injection-related risks (infection, abscess, contamination from non-sterile product), unknown long-term / off-target effects. How often they occur is not established for all of them. Use caution if any of these apply to you: Pregnancy and breastfeeding — never studied; avoid entirely; Any use expecting a regulated, quality-controlled medicine — MOTS-c is a research chemical, not an approved drug or supplement; Diabetes medication without medical supervision — MOTS-c modulates glucose/insulin pathways in animals; unpredictable additive effects in humans are unstudied.
Semaglutide
Too few graded studiesAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is a prescription drug, not a supplement, and is never auto-recommended.
Tirzepatide
Too few graded studiesAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a US FDA boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Liraglutide
Too few graded studiesAn FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. It is a prescription medicine, NOT a supplement, and is not auto-recommended.
Dulaglutide
Too few graded studiesAn FDA-approved once-weekly GLP-1 receptor agonist (brand Trulicity) for type 2 diabetes, with genuinely strong, large-RCT evidence for lowering HbA1c plus a dedicated cardiovascular-outcomes trial (REWIND) showing a ~12% reduction in major cardiovascular events. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and modest (not semaglutide-tier) weight loss. It is a prescription drug, not a supplement, and is never auto-recommended.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 19 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research